Loading...

QuidelOrtho Corporation

QDELNASDAQ
Healthcare
Medical - Instruments & Supplies
$27.90
$2.24(8.73%)

QuidelOrtho Corporation (QDEL) Financial Performance & Income Statement Overview

Analyze QuidelOrtho Corporation (QDEL) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.

Revenue Growth
-7.17%
7.17%
Operating Income Growth
-1509.71%
1509.71%
Net Income Growth
-20216.83%
20216.83%
Operating Cash Flow Growth
-70.38%
70.38%
Operating Margin
-1.94%
1.94%
Gross Margin
45.57%
45.57%
Net Profit Margin
-17.00%
17.005%
ROE
-15.60%
15.60%
ROIC
-1.02%
1.02%

QuidelOrtho Corporation (QDEL) Income Statement & Financial Overview

Review QuidelOrtho Corporation QDEL income statement with detailed quarterly and annual figures.

MetricQ2 2025Q1 2025Q4 2024Q3 2024
Revenue$613.90M$692.80M$707.80M$727.10M
Cost of Revenue$47.90M$48.00M$381.70M$374.80M
Gross Profit$566.00M$644.80M$326.10M$352.30M
Gross Profit Ratio$0.92$0.93$0.46$0.48
R&D Expenses$45.70M$53.20M$47.30M$55.90M
SG&A Expenses$178.00M$187.00M$187.50M$186.40M
Operating Expenses$223.70M$240.20M$426.50M$337.30M
Total Costs & Expenses$271.60M$288.20M$808.20M$712.10M
Interest Income$0.00$0.00$0.00$0.00
Interest Expense$40.50M$42.30M$44.70M$49.90M
Depreciation & Amortization$0.00$107.10M$109.30M$113.10M
EBITDA$342.30M$140.60M$13.10M$133.80M
EBITDA Ratio$0.56$0.20$0.02$0.18
Operating Income$342.30M$32.60M-$100.40M$15.00M
Operating Income Ratio$0.56$0.05-$0.14$0.02
Other Income/Expenses (Net)-$571.90M-$41.40M-$40.50M-$43.80M
Income Before Tax-$229.60M-$8.80M-$140.90M-$28.80M
Income Before Tax Ratio-$0.37-$0.01-$0.20-$0.04
Income Tax Expense$25.80M$3.90M$12.50M-$8.90M
Net Income-$255.40M-$12.70M-$178.40M-$19.90M
Net Income Ratio-$0.42-$0.02-$0.25-$0.03
EPS-$3.77-$0.19-$2.28-$0.30
Diluted EPS-$3.77-$0.19-$2.28-$0.30
Weighted Avg Shares Outstanding$67.70M$67.50M$67.20M$67.30M
Weighted Avg Shares Outstanding (Diluted)$67.70M$67.50M$67.20M$67.30M

Financial performance has remained strong, with revenue growing from $727.10M in Q3 2024 to $613.90M in Q2 2025. Gross profit continued to perform well, with margins at 92% in the latest quarter. Operating income reached $342.30M in Q2 2025, holding a steady 56% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $342.30M. Net income dropped to -$255.40M, keeping EPS at -$3.77. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;